Overcoming Manufacturing Challenges for Gene-Enabled Cell Therapies
Summary: Cell and gene therapies constitute a dynamic market with unprecedented growth. As new therapeutics are entering the market with double digit growth, existing therapies are also moving through late-stage clinical phases. Capacity constraints, especially in viral vector manufacturing, can impact the downstream supply chain tied to gene-enabled cell therapies. This highlights the importance of partnering with manufacturers who possess integrated capabilities across the full value chain along with early to late stage capacity to allow therapeutic programs to evolve efficiently. For this webinar, hosted in partnership with Catalent, join us as our panel of experts discuss key manufacturing challenges for early and late-stage gene-enabled cell therapy programs, as well as how to overcome them through effective partnerships.